COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04340557

George Sakoulas

Katie Miller, kathryn.miller@sharp.com (PI email not reported)

2020-04-09

Completed

RCT

Randomized

Parallel

Open label

multi-center

Treatment

inclusion criteria: - confirmed covid-19 positive test result - mild to moderate respiratory symptoms of covid-19. - systolic blood pressure ≥ 105 mmhg. - screen within 3 days of a positive covid-19 test. - age ≥18 years old. - access to a phone in the hospital room or an electronic device that is capable of receiving phone or video calls. - able to read/write/speak english or spanish fluently. - subjects must have the capacity to provide consent or an appropriate lar to provide informed consent. - negative pregnancy test for women of childbearing potential and subject is randomized to the study arm.

- severe allergy to any arb or ace-inhibitor, including angioedema - in the intensive care unit at screening. - home meds include any kind of ace inhibitor or arb - acute kidney injury (50% reduction in gfr from baseline at admission to any time during treatment in the study treatment arm) - hyperkalemia >5.0 mmol/l at baseline or any time during treatment in the study treatment arm - creatinine clearance < 30 ml/min at baseline or any time during treatment in the study treatment arm

2

Sharp HealthCare

18

None

United States

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

31

Mechanical ventilation

None

Phase 4

[{"arm_notes": "", "treatment_id": 744, "treatment_name": "Losartan", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]